- 专利标题: Co-agonists of the glucagon and GLP-1 receptors
-
申请号: US15519565申请日: 2015-10-22
-
公开(公告)号: US10413593B2公开(公告)日: 2019-09-17
- 发明人: Elisabetta Bianchi , Paul E. Carrington , Qiaolin Deng , Ravi Nargund , Federica Orvieto , Anandan Palani , Antonello Pessi , Thomas Joseph Tucker , Chengwei Wu
- 申请人: MERCK SHARP & DOHME CORP.
- 申请人地址: US NJ Rahway
- 专利权人: Merck Sharp & Dohme Corp.
- 当前专利权人: Merck Sharp & Dohme Corp.
- 当前专利权人地址: US NJ Rahway
- 代理商 Baerbel R. Brown; Catherine D. Fitch
- 国际申请: PCT/US2015/056794 WO 20151022
- 国际公布: WO2016/065090 WO 20160428
- 主分类号: C07K14/605
- IPC分类号: C07K14/605 ; A61K38/26 ; A61K38/28
摘要:
Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
公开/授权文献
- US20170360893A1 CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS 公开/授权日:2017-12-21